search button
Open Access

Role of high‑sensitivity C‑reactive protein in patients with sarcoma

  • Authors:
    • Ninna Aggerholm‑Pedersen
    • Thomas Baad‑Hansen
    • Holger Jon Møller
    • Birgitte Sandfeld‑Paulsen

  • View Affiliations

  • Published online on: October 30, 2023     https://doi.org/10.3892/ol.2023.14118
  • Article Number: 531

  • Copyright: © Aggerholm‑Pedersen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immunotherapy has shown promising results in lung cancer and melanomas; however, the responses have been poor in patients with sarcoma. Understanding the relationship between the immune system and sarcoma is essential to develop improved immunotherapy approaches. High‑sensitivity C‑reactive protein (hs‑CRP) has been proposed as a prognostic marker in other cancer types; however, to the best of our knowledge, the association between hs‑CRP levels and mortality in patients with sarcoma has not been investigated. The present prospective, non‑randomised, non‑interventional explorative study investigated the prognostic value of hs‑CRP in patients with sarcoma. Patients referred to the sarcoma centre of Aarhus University Hospital (Aarhus, Denmark) were included between April 2014 and December 2020. Clinical data were obtained from the national quality sarcoma database and biomarkers other than hs‑CRP were obtained from the clinical laboratory information system. The study cohort consisted primarily of patients with localised sarcoma. hs‑CRP was significantly higher in patients with bone sarcoma (P=0.022) and soft tissue sarcoma (STS; P<0.001) compared with control patients. For STS, grade III tumours but not metastatic disease were associated with a higher hs‑CRP level (P=0.0001). Elevated hs‑CRP levels were associated with increased overall mortality [hazard ratio (HR), 1.91; 95% CI, 1.33‑2.75; P=0.001]. Furthermore, elevated hs‑CRP levels were also associated with decreased progression‑free survival (HR, 1.64; 95% CI, 1.17‑2.29; P=0.004). Furthermore, for patients with hs‑CRP <8 mg/l, higher hs‑CRP was associated with an increased risk of recurrent disease and reduced overall survival compared with those of patients with low hs‑CRP. In conclusion, the present study demonstrated that hs‑CRP was a prognostic factor for overall mortality and progression‑free survival in patients with localised sarcoma at the time of diagnosis. Further studies are required to investigate the mechanism behind the association between hs‑CRP and sarcoma prognosis and its potential use in clinical practice.
View Figures
View References

Related Articles

Journal Cover

December-2023
Volume 26 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Aggerholm‑Pedersen N, Baad‑Hansen T, Møller HJ and Sandfeld‑Paulsen B: Role of high‑sensitivity C‑reactive protein in patients with sarcoma. Oncol Lett 26: 531, 2023
APA
Aggerholm‑Pedersen, N., Baad‑Hansen, T., Møller, H.J., & Sandfeld‑Paulsen, B. (2023). Role of high‑sensitivity C‑reactive protein in patients with sarcoma. Oncology Letters, 26, 531. https://doi.org/10.3892/ol.2023.14118
MLA
Aggerholm‑Pedersen, N., Baad‑Hansen, T., Møller, H. J., Sandfeld‑Paulsen, B."Role of high‑sensitivity C‑reactive protein in patients with sarcoma". Oncology Letters 26.6 (2023): 531.
Chicago
Aggerholm‑Pedersen, N., Baad‑Hansen, T., Møller, H. J., Sandfeld‑Paulsen, B."Role of high‑sensitivity C‑reactive protein in patients with sarcoma". Oncology Letters 26, no. 6 (2023): 531. https://doi.org/10.3892/ol.2023.14118